Background: One of the key issues in the treatment of adrenocortical carcinoma is the efficacy of repeat resection of local recurrence and metastatic disease in affected patients. Options in the treatment of locally recurrent or metastatic disease are limited because chemotherapy and radiotherapy generally do not provide any significant prolongation in survival in treated patients.
Methods: A series of 113 patients who presented to Memorial Sloan-Kettering Cancer Center for treatment of adrenocortical carcinoma are presented.
Results: The median overall survival for all 113 patients was 38 months (5-year survival, 37%). Patients presenting with early stage I or II disease (n = 57) had a median survival of 101 months (5-year survival, 60%), whereas those with late stage III or IV disease (n = 56) had a median survival of 15 months (5-year survival, 10%). Patients who had complete primary resection (n = 68) had a median survival of 74 months (5-year survival, 55%), whereas those with incomplete primary resection (n = 45) had a median survival of 12 months (5-year survival, 5%). Resection of locally recurrent or distant metastatic disease was performed in 47 of these patients. Patients who had a complete second resection had a median survival of 74 months (5-year survival, 57%), whereas those with incomplete second resection had a median survival of 16 months (5-year survival, 0%).
Conclusions: Improved survival is seen in patients who present with early stage and have complete primary resection. Patients who undergo complete repeat resection of local recurrence or distant metastasis also have improved survival. Complete repeat resection was more readily accomplished in discrete distant metastatic lesions compared with bulky local recurrences.
Plager JE. Carcinoma of the adrenal cortex: clinical description, diagnosis, and treatment. Int Adv Surg Oncol 1984;7:329–353.PubMedGoogle Scholar
Hamwi GJ, Serbin RA, Kruger FA. Does adrenocortical hyperplasia result in adrenocortical carcinoma? N Engl J Med 1957;257:1153–1157.CrossRefPubMedGoogle Scholar
Yano T, Linehan M, Anglard P, et al. Genetic changes in human adrenocortical carcinoma. J Natl Cancer Inst 1989;81:518–523.PubMedGoogle Scholar
Henry I, Grandjovans S, Couillin P, et al. Tumor-specific loss of 11p15.5 alleles in del11p13 Wilms tumor and in familial adrenocortical carcinoma. Proc Natl Acad Sci USA 1989;86:3247–3251.PubMedGoogle Scholar
Ohgaki H, Kleihues P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. Int J Cancer 1993;54:408–410.PubMedGoogle Scholar
Reincke M, Karl M, Travis WH, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994;78:790–794.PubMedGoogle Scholar
Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992;112:963–971.PubMedGoogle Scholar
Icard P, Chapuis Y, Adnreassian B, Bernard A, Proye C. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992;112:972–980.PubMedGoogle Scholar
Zografos GC, Driscoll DL, Karakousis CP, Huben RP. Adrenal adenocarcinoma: a review of 53 cases. J Surg Onc 1994;55:160–164.Google Scholar
Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994;69:947–951.PubMedGoogle Scholar
Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P, The ACC Italian Registry Study Group. The Italian registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients. Surgery 1996;119:161–170.PubMedGoogle Scholar
Harrison LE, Gaudin P, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Ann Surg Oncol 1999; in press.Google Scholar
Venkatesh S, Hickey RC, Sellin RV, Fernandez JF, Samaan NA. Adrenal cortical carcinoma. Cancer 1989;64:765–769.PubMedGoogle Scholar
Luton J, Cerdas S, Line B, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322:1195–1201.CrossRefPubMedGoogle Scholar